Small Molecules for Musculoskeletal Diseases

Edgewise Therapeutics is focused on developing innovative therapies for serious muscle diseases, particularly targeting skeletal and cardiac muscle disorders. The company is advancing two key investigational therapies: sevasemten and EDG-7500. Sevasemten is a first-in-class fast skeletal myosin inhibitor designed for oral administration, aimed at preserving and protecting unstable muscle from contraction-induced injuries in patients with rare skeletal muscle disorders, such as Becker and Duchenne muscular dystrophies. Clinical trials, including the CANYON and LYNX studies, are underway to evaluate its safety and efficacy in various patient populations.

On the cardiac side, Edgewise is developing EDG-7500, a novel oral selective cardiac sarcomere modulator intended to address hypertrophic cardiomyopathy (HCM). This therapy aims to slow the excessive rate of early contraction and improve impaired cardiac relaxation associated with both obstructive and non-obstructive forms of HCM. Ongoing clinical trials, such as the CIRRUS-HCM study, are assessing the safety, tolerability, and pharmacodynamics of EDG-7500 in adults. Through these efforts, Edgewise Therapeutics is committed to addressing unmet medical needs in muscle diseases and improving patient outcomes.

United States

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.

Cardiovascular Diseases

Genetic Diseases

Musculoskeletal Diseases

Nervous System Diseases

Edgewise Therapeutics

Becker Muscular Dystrophy

<p class="font_7">EDG-5506 was designed to arrest muscle fiber break down, the hallmark of ongoing disease in muscular dystrophy (MD) patients, thus limiting the subsequent inflammatory and fibrotic response while promoting muscle integrity and physical function. This approach has the potential to benefit a broad population of MD patients and represents a new strategy for treating this devastating disease.</p>

Sevasemten (EDG-5506)

Duchenne muscular dystrophy

Rare diseases

Limb-Girdle Muscular Dystrophy

McArdle disease

Sevasemten (EDG-5506) 

Heart disease

Hypertrophic cardiomyopathies

<p class="font_7">EDG-7500, a first-in-class oral, selective, sarcomere modulator for diseases of diastolic dysfunction</p>

Edgewise Therapeutics

Company Details